Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 16/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1778706 | 1.00 | HCRTR1 (0.42) | HCRTR1HCRTR2RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL1776678 | 0.97 | HCRTR1 (0.43) | HCRTR1HCRTR2RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL1776681 | 0.97 | HCRTR1 (0.43) | HCRTR1HCRTR2RAB9ASMN1; SMN2HDAC1 | |
| SCHEMBL1777293 | 0.91 | HCRTR1 (0.42) | HCRTR1HCRTR2HDAC1 | |
| SCHEMBL1777296 | 0.91 | HCRTR1 (0.42) | HCRTR1HCRTR2HDAC1 | |
| SCHEMBL1778496 | 0.90 | ABHD6 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL1778875 | 0.89 | KCNH2 (0.42) | HCRTR1HCRTR2HDAC1 | |
| SCHEMBL1778712 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2RAB9ASMN1; SMN2 | |
| SCHEMBL1778710 | 0.84 | HCRTR1 (0.41) | HCRTR1HCRTR2RAB9ASMN1; SMN2 | |
| SCHEMBL1256734 | 0.82 | HCRTR1 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | claimed |
| US-7943645-B2 | Piperidine compounds for use as orexin receptor antagonist | SMITHKLINE BEECHAM LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. | 2009-03-26 | — | — | US | disclosed |
| US-7423052-B2 | Piperidine compounds for use as orexin receptor antagoinst | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-09-09 | — | — | US | disclosed |
| EP-1406897-B1 | COMPOUNDS | SMITHKLINE BEECHAM PLC (GB) | 2007-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082390-A1 | PIPERIDINE COMPOUNDS FOR USE AS OREXIN RECEPTOR ANTAGONIST | HCRTR2, HCRTR1, OXTR | HCRTR1 2/4885HCRTR2 1/4885RAB9A 1592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.